Inozyme Outlines Plans For Pediatric Trial For ENPP1 Deficiency Treatment: Targets 2026 Commercial Launch For INZ-701
Portfolio Pulse from Vandana Singh
Inozyme Pharma Inc (NASDAQ:INZY) has updated its global development strategy for INZ-701, a treatment for ENPP1 Deficiency, following meetings with the FDA and the European Medicines Agency's Paediatric Committee. The company plans to initiate the ENERGY-3 pivotal trial in October 2023 and aims to commercially launch INZ-701 for infant and pediatric patients by the second half of 2026. The company's cash balance of $140.2 million is expected to provide a cash runway into the first quarter of 2025. INZY shares are down 11.40% at $5.47.
July 26, 2023 | 6:45 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Inozyme Pharma's plans for INZ-701 could potentially boost its stock in the long term, but currently, the shares are down 11.40%.
The company's plans for INZ-701 and its solid cash balance could be positive for the stock in the long term. However, in the short term, the stock is down, possibly due to market reactions to the news or other factors.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100